Bayer HealthCare invests US$100m in new US product testing facility for haemophilia treatments

Published: 20-Apr-2015

Investment represents the company's dedication to science and innovation in the life sciences

Bayer HealthCare is to invest US$100m in its Berkeley manufacturing site to build a product testing facility that will support the next generation of treatments for patients with haemophilia A.

‘Building on our legacy in haemophilia A, we are delighted to continue Bayer's leadership in working to bring treatment options to patients around the world,’ said Jörg Heidrich, Senior Vice President for Product Supply Biotech and Site Head at Bayer Berkeley.

Bayer has a long history in haemophilia, with more than 25 years of research and development on products and approaches to meet the varied needs of patients with haemophilia A.

‘The new product testing facility will assess Bayer's investigational products according to rigorous global regulatory requirements,’ said David Weinreich, MD, Head, Global Development, Specialty Medicine at Bayer. ‘We are thrilled to further strengthen our commitment to the haemophilia A patient community that Bayer has served for more than 25 years.’

You may also like